Increased both PD–L1 and PD–L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis

Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis

(2019) Huayu Yang et al.   Frontiers in Oncology

Hepatocellular Carcinoma

(2019) Augusto Villanueva   NEW ENGLAND JOURNAL OF MEDICINE

Liver Cancer Cell Lines Treated with Doxorubicin under Normoxia and Hypoxia: Cell Viability and Oncologic Protein Profile

(2019) Ilse R. Dubbelboer et al.   Cancers

Mechanisms Controlling PD-L1 Expression in Cancer

(2019) Jong-Ho Cha et al.   MOLECULAR CELL

Mechanisms of resistance to immune checkpoint inhibitors

(2018) Russell W Jenkins et al.   BRITISH JOURNAL OF CANCER

Regulation and Function of the PD-L1 Checkpoint

(2018) Chong Sun et al.   IMMUNITY

MicroRNA-374b inhibits liver cancer progression via down regulating programmed cell death-1 expression on cytokine-induced killer cells

(2018) Fen Huang et al.   Oncology Letters

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis

(2018) Xian Shen et al.   BMJ-British Medical Journal

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Yoon-Koo Kang et al.   LANCET

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Expression and clinical significance of programmed death‑1 on lymphocytes and programmed death ligand‑1 on monocytes in the peripheral blood of patients with cervical cancer

(2017) Ying Zhang et al.   Oncology Letters

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

(2017) Hashem O. Alsaab et al.   Frontiers in Pharmacology

Host antitumor resistance improved by the macrophage polarization in a chimera model of patients with HCC

(2017) Akira Asai et al.   OncoImmunology

PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma

(2017) Kostandinos Sideras et al.   OncoImmunology

A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma

(2016) Mashaal Dhir et al.   ANNALS OF SURGERY

Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy

(2016) Se Jin Im et al.   NATURE

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

(2015) Luisa Carbognin et al.   PLoS One

New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape

(2014) Deepak Mittal et al.   CURRENT OPINION IN IMMUNOLOGY

Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer

(2013) Christian J. Maine et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response

(2013) Giuseppe Cabibbo et al.   PLoS One

M2b Monocytes Predominated in Peripheral Blood of Severely Burned Patients

(2010) M. Kobayashi et al.   JOURNAL OF IMMUNOLOGY

Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

(2009) Q. Gao et al.   CLINICAL CANCER RESEARCH

PD-1-Mediated Suppression of IL-2 Production Induces CD8+ T Cell Anergy In Vivo

(2009) S. Chikuma et al.   JOURNAL OF IMMUNOLOGY